Focused On-demand Library for Conserved oligomeric Golgi complex subunit 5

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.

From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.

The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.

We use our state-of-the-art dedicated workflow for designing focused libraries.

Fig. 1. The sreening workflow of Receptor.AI

By deploying molecular simulations, our approach comprehensively covers a broad array of proteins, tracking their flexibility and dynamics individually and within complexes. Ensemble virtual screening is utilised to take into account conformational dynamics, identifying pivotal binding sites located within functional regions and at allosteric locations. This thorough exploration ensures that every conceivable mechanism of action is considered, aiming to identify new therapeutic targets and advance lead compounds throughout a vast spectrum of biological functions.

Our library stands out due to several important features:

The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.
Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.
Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.
Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.

partner

Reaxense

upacc

Q9UP83

UPID:

COG5_HUMAN

Alternative names:

13S Golgi transport complex 90 kDa subunit; Component of oligomeric Golgi complex 5; Golgi transport complex 1

Alternative UPACC:

Q9UP83; A4D0R6; A4D0R7; O14555; O95008; Q6NUL5

Background:

The Conserved oligomeric Golgi complex subunit 5, known by its alternative names such as 13S Golgi transport complex 90 kDa subunit, Component of oligomeric Golgi complex 5, and Golgi transport complex 1, plays a pivotal role in maintaining normal Golgi function. This protein is integral to the process of glycoprotein biosynthesis, ensuring the proper assembly and function of glycoproteins within the cell.

Therapeutic significance:

The protein's malfunction is directly linked to Congenital disorder of glycosylation 2I, a multisystem disorder characterized by a broad spectrum of clinical features including neurological impairments, psychomotor retardation, and immunodeficiency. Understanding the role of Conserved oligomeric Golgi complex subunit 5 could open doors to potential therapeutic strategies for this disorder, highlighting its critical role in embryonic development and cell function maintenance.